Risk of seizures in transcranial magnetic stimulation: A clinical review to inform consent process focused on bupropion

Neuropsychiatric Disease and Treatment

Volumn 11, Issue , 2015, Pages 2975-2987

  Dobek, Christine E ^a   Blumberger, Daniel M ^b   Downar, Jonathan ^c   Daskalakis, Zafiris J ^b   Vila Rodriguez, Fidel ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Bupropion; Consent process; Interaction; Repetitive transcranial magnetic stimulation; Seizures

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMPHETAMINE; CHLORDIAZEPOXIDE; CHLORPROMAZINE; DESVENLAFAXINE; DIAZEPAM; FLUOXETINE; GABAPENTIN; HALOPERIDOL; HYDROXYZINE; LITHIUM; LORAZEPAM; OLANZAPINE; PAROXETINE; QUETIAPINE; SERTRALINE; THYROXINE; TRAZODONE;

BIPOLAR DEPRESSION; BIPOLAR DISORDER; COMPLEX PARTIAL SEIZURE; DEPENDENT PERSONALITY DISORDER; DEPRESSIVE PSYCHOSIS; HEADACHE; HUMAN; HYPOTHYROIDISM; INFORMED CONSENT; MAJOR DEPRESSION; MIXED ANXIETY AND DEPRESSION; NEUROLOGIC DISEASE; POLYPHARMACY; REFERENCE DATABASE; REVIEW; RISK ASSESSMENT; SEIZURE; SEXUAL DYSFUNCTION; SLEEP DEPRIVATION; SYSTEMATIC REVIEW (TOPIC); TONIC CLONIC SEIZURE; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 84949551175     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S91126     Document Type: Review

References (60)

1. Kennedy SH, Milev R, Giacobbe P, et al; Canadian Network for Mood and Anxiety Treatments (CANMAT). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. IV. Neurostimulation therapies. J Affect Disord. 2009; 117: S44-S53.
2. Jhanwar VG, Bishnoi RJ, Jhanwar MR. Utility of repetitive transcranial stimulation as an augmenting treatment method in treatment-resistant depression. Indian J Psychol Med. 2011; 33(1): 92-96.
3. Rossi S, Hallett M, Rossini PM, Pascual-Leone A; Safety of TMS Consensus Group. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol. 2009; 120: 2008.
4. Tripp AC. Bupropion, a brief history of seizure risk. Gen Hosp Psychiatry. 2010; 32(2): 216-217.
5. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006; 354(12): 1243-1252.
6. Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord. 2009; 117: S26-S43.
7. Dhillon S, Yang LP, Curran MP. Bupropion. Drugs. 2008; 68(5): 653-689.
8. Damaj MI, Carroll FI, Eaton JB, et al. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol. 2004; 66(3): 675-682.
9. Coleman CC, King BR, Bolden-Watson C, et al. A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Ther. 2001; 23(7): 1040-1058.
10. Croft H, Settle E Jr, Houser T, Batey SR, Donahue RM, Ascher JA. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther. 1999; 21(4): 643-658.
11. Papakostas GI, Nutt DJ, Hallett LA, Tucker VL, Krishen A, Fava M. Resolution of sleepiness and fatigue in major depressive disorder: a comparison of bupropion and the selective serotonin reuptake inhibitors. Biol Psychiatry. 2006; 60(12): 1350-1355.
12. U. S. Food and Drug Administration. Wellbutrin XL (Bupropion Hydrochloride Extended-Release Tablets). Silver Spring, MD: U. S. Food and Drug Administration; 2011.
13. Zimmerman M, Posternak MA, Attiullah N, et al. Why isn't bupropion the most frequently prescribed antidepressant? J Clin Psychiatry. 2005; 66(5): 603-610.
14. Dording CM, Mischoulon D, Petersen TJ, et al. The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists. Ann Clin Psychiatry. 2002; 14(3): 143-147.
15. Horne RL, Ferguson JM, Pope HG Jr, et al. Treatment of bulimia with bupropion: a multicenter controlled trial. J Clin Psychiatry. 1988; 49(7): 262-266.
16. Vila-Rodriguez F, Downar J, Blumberger DM. Repetitive transcranial magnetic stimulation in depression: a changing landscape. Psychiatric Times. 2013: 1-3. Available from: http://www. psychiatrictimes. com/depression/repetitive-transcranial-magnetic-stimulation-depression-changing-landscape. Accessed October 12, 2015.
17. Conca A, Di Pauli J, Beraus W, et al. Combining high and low frequencies in rTMS antidepressive treatment: preliminary results. Hum Psychopharmacol. 2002; 17(7): 353-356.
18. Daskalakis ZJ, Christensen BK, Fitzgerald PB, Chen R. Transcranial magnetic stimulation a new investigational and treatment tool in psychiatry. J Neuropsychiatry Clin Neurosci. 2002; 14(4): 406-415.
19. George MS, Lisanby SH, Sackeim HA. Transcranial magnetic stimulation: applications in neuropsychiatry. Arch Gen Psychiatry. 1999; 56(4): 300-311.
20. Loo CK, McFarquhar TF, Mitchell PB. A review of the safety of repetitive transcranial magnetic stimulation as a clinical treatment for depression. Int J Neuropsychopharmacol. 2008; 11(01): 131-147.
21. Machii K, Cohen D, Ramos-Estebanez C, Pascual-Leone A. Safety of rTMS to non-motor cortical areas in healthy participants and patients. Neurophysiol Clin. 2006; 117(2): 455-471.
22. Maizey L, Allen CP, Dervinis M, et al. Comparative incidence rates of mild adverse effects to transcranial magnetic stimulation. Neurophysiol Clin. 2013; 124(3): 536-544.
23. Wassermann EM. Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the international workshop on the safety of repetitive transcranial magnetic stimulation, June 5-7, 1996. Electroencephalogr Clin Neurophysiol. 1998; 108(1): 1-16.
24. Chiramberro M, Lindberg N, Isometsä E, Kähkönen S, Appelberg B. Repetitive transcranial magnetic stimulation induced seizures in an adolescent patient with major depression: a case report. Brain Stimulat. 2013; 6(5): 830-831.
25. Bagati D, Mittal S, Praharaj SK, Sarcar M, Kakra M, Kumar P. Repetitive transcranial magnetic stimulation safely administered after seizure. J ECT. 2012; 28(1): 60-61.
26. Hu SH, Wang SS, Zhang MM, et al. Repetitive transcranial magnetic stimulation-induced seizure of a patient with adolescent-onset depression: a case report and literature review. J Int Med Res. 2011; 39(5): 2039-2044.
27. Harel EV, Zangen A, Roth Y, Reti I, Braw Y, Levkovitz Y. H-coil repetitive transcranial magnetic stimulation for the treatment of bipolar depression: an add-on, safety and feasibility study. World J Biol Psychiatry. 2011; 12(2): 119-126.
28. Gómez L, Morales L, Trápaga O, et al. Seizure induced by sub-threshold 10-Hz rTMS in a patient with multiple risk factors. Neurophysiol Clin. 2011; 122(5): 1057-1058.
29. Rosa MA, Picarelli H, Teixeira MJ, Rosa MO, Marcolin MA. Accidental seizure with repetitive transcranial magnetic stimulation. J ECT. 2006; 22(4): 265-266.
30. Sakkas P, Theleritis CG, Psarros C, Papadimitriou GN, Soldatos CR. Jacksonian seizure in a manic patient treated with rTMS. World J Biol Psychiatry. 2008; 9(2): 159-160.
31. Prikryl R, Kucerova H. Occurrence of epileptic paroxysm during repetitive transcranial magnetic stimulation treatment. J Psychopharmacol. 2005; 19(3): 313.
32. Bernabeu M, Orient F, Tormos JM, Pascual-Leone A. Seizure induced by fast repetitive transcranial magnetic stimulation. Neurophysiol Clin. 2004; 115(7): 1714-1715.
33. Conca A, König P, Hausmann A. Transcranial magnetic stimulation induces 'pseudoabsence seizure'. Acta Psychiatr Scand. 2000; 101(3): 246-249.
34. Wassermann E, Cohen L, Flitman S, Chen R, Hallett M. Seizures in healthy people with repeated "safe" trains of transcranial magnetic stimuli. Lancet. 1996; 347(9004): 825-826.
35. Tharayil BS, Gangadhar BN, Thirthalli J, Anand L. Seizure with single-pulse transcranial magnetic stimulation in a 35-year-old otherwise-healthy patient with bipolar disorder. J ECT. 2005; 21(3): 188-189.
36. Fauth C, Meyer B, Prosiegel M, Zihl J, Conrad B. Seizure induction and magnetic brain stimulation after stroke. Lancet. 1992; 339(8789): 362.
37. Hömberg V, Netz J. Generalised seizures induced by transcranial magnetic stimulation of motor cortex. Lancet. 1989; 334(8673): 1223.
38. Kandler R. Safety of transcranial magnetic stimulation. Lancet. 1990; 335(8687): 469-470.
39. Oberman LM, Pascual-Leone A. Report of seizure induced by continuous theta burst stimulation. Brain Stimul. 2009; 2(4): 246-247.
40. Brogmus K. Provokation eines epileptischen Anfalls durch transkranielle Magnetstimulation-eine Falldarstellung. Aktuelle Neurol. 1998; 25(04): 156-158.
41. Pascual-Leone A, Valls-Solé J, Brasil-Neto J, Cohen LG, Hallett M. Seizure induction and transcranial magnetic stimulation. Lancet. 1992; 339(8799): 997.
42. Chervyakov A, Piradov M, Chernikova L, et al. Capability of navigated repeated transcranial magnetic stimulation in stroke rehabilitation (Randomized blind sham-controlled study). Journal of the Neurological Sciences. 2013; 333(1): 246-247.
43. Wall C, Croarkin P, Bandel L, et al. Response to repetitive transcranial magnetic stimulation induced seizures in an adolescent patient with major depression: a case report. Brain Stimulation. 2014; 7(2): 337-338.
44. U. S. Food and Drug Administration. MAUDE Adverse Event Reporting: Neuronetics TMS. 2011; 3004824012-2011-00004.
45. Mufti MA, Holtzheimer III PE, Epstein CM, et al. Bupropion decreases resting motor threshold: a case report. Brain stimulation. 2010; 3(3): 177-180.
46. Wassermann EM. Variation in the response to transcranial magnetic brain stimulation in the general population. Clinical Neurophysiology. 2002; 113(7): 1165-1171.
47. Pfizer-Roerig. Zoloft (sertraline hydrochloride). Pfizer Canada Inc. 2012.
48. Eli Lilly and Company. Prozac (fluoxetine hydrochloride). Eli Lilly Canada Inc. 2008.
49. GenMed PC. Mirtazapine Product Monograph. 2012.
50. Pfizer. Effexor XR Capsules (Venlafaxine Hydrochloride) Product Monograph. 2013.
51. Eli Lilly and Company. Cymbalta (Duloxetine) Product Monograph. 2012.
52. Edwards JG, Inman WH, Wilton L, et al. Prescription-event monitoring of 10, 401 patients treated with fluvoxamine. Br J Psychiatry. 1994; 164(3): 387-395.
53. Lundbeck Canada Inc. Celexa (Citalopram hydrobromide) Product Monograph. 2012.
54. GlaxoSmithKline Inc. Paxil (Paroxetine) Product Monograph. 2012.
55. Alper K, Schwartz KA, Kolts RL, Khan A. Seizure incidence in Psychopharmacological Clinical Trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biological Psychiatry. 2007; 62: 345-354.
56. Preskorn S, Fast G. Tricyclic antidepressant-induced seizures and plasma drug concentration. 2002; 53(5): 160-162.
57. Hauser WA, Kurland LT. The epidemiology of epilepsy in Rochester, Minnesota, 1935 through 1967. Epilepsia. 1975; 16(1): 1-66.
58. Janicak PG, O'Reardon JP, Sampson SM, et al. Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. J Clin Psychiatry. 2008; 69(2): 222-232.
59. Kleinjung T, Steffens T, Landgrebe M, et al. Repetitive transcranial magnetic stimulation for tinnitus treatment: no enhancement by the dopamine and noradrenaline reuptake inhibitor bupropion. Brain stimulation. 2011; 4(2): 65-70.
60. Cantello R, Rossi S, Varrasi C, et al. Slow repetitive TMS for drug-resistant epilepsy: clinical and EEG findings of a placebo-controlled trial. Epilepsia. 2007; 48(2): 366-374.